Lilly's Alzheimer’s drug that can slow disease gets backing from FDA advisers

A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia caused by the brain-robbing disease.